APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Ankylosing Spondylitis Treatment Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Ankylosing Spondylitis Treatment Drug Industry Growth and Trends Forecast to 2032

Report ID 173964340131 December 2025110 pages

Choose your research edition.

Industry ResearchAnkylosing Spondylitis Treatment Drug Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Ankylosing Spondylitis Treatment Drug Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Ankylosing Spondylitis Treatment Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Ankylosing Spondylitis Treatment Drug Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Ankylosing Spondylitis Treatment Drug Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

According to APO Research, the global Ankylosing Spondylitis Treatment Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Ankylosing Spondylitis Treatment Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Ankylosing Spondylitis Treatment Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Ankylosing Spondylitis Treatment Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Ankylosing Spondylitis Treatment Drug market include UCB, Abbott, Takeda, Eisai, Guojian Pharmaceutical, Celgen Pharm, Johson & Johson, Novartis and Merck, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Ankylosing Spondylitis Treatment Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Ankylosing Spondylitis Treatment Drug market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Ankylosing Spondylitis Treatment Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Ankylosing Spondylitis Treatment Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Ankylosing Spondylitis Treatment Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Ankylosing Spondylitis Treatment Drug Market by Company

UCB

Abbott

Takeda

Eisai

Guojian Pharmaceutical

Celgen Pharm

Johson & Johson

Novartis

Merck

Maibo Pharma

Pfizer

Hisun Pharm

Bio-Thera Solutions

Amgen

Abbive

Mitsubishi Tanabe

Ankylosing Spondylitis Treatment Drug Segment by Type

Non-steroidal Anti-inflammatory Drugs

Inhibitor

Ankylosing Spondylitis Treatment Drug Segment by Application

Retail Pharmacy

Online Pharmacy

Hospital Pharmacy

Other

Ankylosing Spondylitis Treatment Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ankylosing Spondylitis Treatment Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Ankylosing Spondylitis Treatment Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ankylosing Spondylitis Treatment Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Ankylosing Spondylitis Treatment Drug companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Ankylosing Spondylitis Treatment Drug Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Ankylosing Spondylitis Treatment Drug Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Ankylosing Spondylitis Treatment Drug Market Share by Region (2021-2026) Table 4. Global Ankylosing Spondylitis Treatment Drug Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Ankylosing Spondylitis Treatment Drug Market Share by Region (2027-2032) Table 6. Global Ankylosing Spondylitis Treatment Drug Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Ankylosing Spondylitis Treatment Drug Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Ankylosing Spondylitis Treatment Drug Market Size Share by Type (2021-2026) Table 9. Global Ankylosing Spondylitis Treatment Drug Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Ankylosing Spondylitis Treatment Drug Market Size Share Forecasted by Type (2027-2032) Table 11. North America Ankylosing Spondylitis Treatment Drug Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Ankylosing Spondylitis Treatment Drug Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Ankylosing Spondylitis Treatment Drug Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Ankylosing Spondylitis Treatment Drug Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Ankylosing Spondylitis Treatment Drug Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Ankylosing Spondylitis Treatment Drug Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Ankylosing Spondylitis Treatment Drug Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Ankylosing Spondylitis Treatment Drug Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Ankylosing Spondylitis Treatment Drug Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Ankylosing Spondylitis Treatment Drug Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Ankylosing Spondylitis Treatment Drug Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Ankylosing Spondylitis Treatment Drug Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Ankylosing Spondylitis Treatment Drug Market Size Share by Application (2021-2026) Table 24. Global Ankylosing Spondylitis Treatment Drug Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Ankylosing Spondylitis Treatment Drug Market Size Share Forecasted by Application (2027-2032) Table 26. North America Ankylosing Spondylitis Treatment Drug Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Ankylosing Spondylitis Treatment Drug Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Ankylosing Spondylitis Treatment Drug Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Ankylosing Spondylitis Treatment Drug Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Ankylosing Spondylitis Treatment Drug Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Ankylosing Spondylitis Treatment Drug Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Ankylosing Spondylitis Treatment Drug Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Ankylosing Spondylitis Treatment Drug Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Ankylosing Spondylitis Treatment Drug Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Ankylosing Spondylitis Treatment Drug Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Ankylosing Spondylitis Treatment Drug Industry Trends Table 37. Ankylosing Spondylitis Treatment Drug Industry Drivers Table 38. Ankylosing Spondylitis Treatment Drug Industry Opportunities and Challenges Table 39. Ankylosing Spondylitis Treatment Drug Industry Restraints Table 40. Global Ankylosing Spondylitis Treatment Drug Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Ankylosing Spondylitis Treatment Drug Revenue Market Share by Company (2021-2026) Table 42. Global Ankylosing Spondylitis Treatment Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Ankylosing Spondylitis Treatment Drug Key Company Headquarters & Area Served Table 44. Global Ankylosing Spondylitis Treatment Drug Company, Product Type & Application Table 45. Global Ankylosing Spondylitis Treatment Drug Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Ankylosing Spondylitis Treatment Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. UCB Company Information Table 49. UCB Business Overview Table 50. UCB Ankylosing Spondylitis Treatment Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. UCB Ankylosing Spondylitis Treatment Drug Product Portfolio Table 52. UCB Recent Development Table 53. Abbott Company Information Table 54. Abbott Business Overview Table 55. Abbott Ankylosing Spondylitis Treatment Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Abbott Ankylosing Spondylitis Treatment Drug Product Portfolio Table 57. Abbott Recent Development Table 58. Takeda Company Information Table 59. Takeda Business Overview Table 60. Takeda Ankylosing Spondylitis Treatment Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Takeda Ankylosing Spondylitis Treatment Drug Product Portfolio Table 62. Takeda Recent Development Table 63. Eisai Company Information Table 64. Eisai Business Overview Table 65. Eisai Ankylosing Spondylitis Treatment Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Eisai Ankylosing Spondylitis Treatment Drug Product Portfolio Table 67. Eisai Recent Development Table 68. Guojian Pharmaceutical Company Information Table 69. Guojian Pharmaceutical Business Overview Table 70. Guojian Pharmaceutical Ankylosing Spondylitis Treatment Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Guojian Pharmaceutical Ankylosing Spondylitis Treatment Drug Product Portfolio Table 72. Guojian Pharmaceutical Recent Development Table 73. Celgen Pharm Company Information Table 74. Celgen Pharm Business Overview Table 75. Celgen Pharm Ankylosing Spondylitis Treatment Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. Celgen Pharm Ankylosing Spondylitis Treatment Drug Product Portfolio Table 77. Celgen Pharm Recent Development Table 78. Johson & Johson Company Information Table 79. Johson & Johson Business Overview Table 80. Johson & Johson Ankylosing Spondylitis Treatment Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Johson & Johson Ankylosing Spondylitis Treatment Drug Product Portfolio Table 82. Johson & Johson Recent Development Table 83. Novartis Company Information Table 84. Novartis Business Overview Table 85. Novartis Ankylosing Spondylitis Treatment Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. Novartis Ankylosing Spondylitis Treatment Drug Product Portfolio Table 87. Novartis Recent Development Table 88. Merck Company Information Table 89. Merck Business Overview Table 90. Merck Ankylosing Spondylitis Treatment Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. Merck Ankylosing Spondylitis Treatment Drug Product Portfolio Table 92. Merck Recent Development Table 93. Maibo Pharma Company Information Table 94. Maibo Pharma Business Overview Table 95. Maibo Pharma Ankylosing Spondylitis Treatment Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. Maibo Pharma Ankylosing Spondylitis Treatment Drug Product Portfolio Table 97. Maibo Pharma Recent Development Table 98. Pfizer Company Information Table 99. Pfizer Business Overview Table 100. Pfizer Ankylosing Spondylitis Treatment Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. Pfizer Ankylosing Spondylitis Treatment Drug Product Portfolio Table 102. Pfizer Recent Development Table 103. Hisun Pharm Company Information Table 104. Hisun Pharm Business Overview Table 105. Hisun Pharm Ankylosing Spondylitis Treatment Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. Hisun Pharm Ankylosing Spondylitis Treatment Drug Product Portfolio Table 107. Hisun Pharm Recent Development Table 108. Bio-Thera Solutions Company Information Table 109. Bio-Thera Solutions Business Overview Table 110. Bio-Thera Solutions Ankylosing Spondylitis Treatment Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 111. Bio-Thera Solutions Ankylosing Spondylitis Treatment Drug Product Portfolio Table 112. Bio-Thera Solutions Recent Development Table 113. Amgen Company Information Table 114. Amgen Business Overview Table 115. Amgen Ankylosing Spondylitis Treatment Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 116. Amgen Ankylosing Spondylitis Treatment Drug Product Portfolio Table 117. Amgen Recent Development Table 118. Abbive Company Information Table 119. Abbive Business Overview Table 120. Abbive Ankylosing Spondylitis Treatment Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 121. Abbive Ankylosing Spondylitis Treatment Drug Product Portfolio Table 122. Abbive Recent Development Table 123. Mitsubishi Tanabe Company Information Table 124. Mitsubishi Tanabe Business Overview Table 125. Mitsubishi Tanabe Ankylosing Spondylitis Treatment Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 126. Mitsubishi Tanabe Ankylosing Spondylitis Treatment Drug Product Portfolio Table 127. Mitsubishi Tanabe Recent Development Table 128. North America Ankylosing Spondylitis Treatment Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 129. North America Ankylosing Spondylitis Treatment Drug Market Size by Country (2021-2026) & (US$ Million) Table 130. North America Ankylosing Spondylitis Treatment Drug Market Share by Country (2021-2026) Table 131. North America Ankylosing Spondylitis Treatment Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 132. North America Ankylosing Spondylitis Treatment Drug Market Share Forecast by Country (2027-2032) Table 133. Europe Ankylosing Spondylitis Treatment Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 134. Europe Ankylosing Spondylitis Treatment Drug Market Size by Country (2021-2026) & (US$ Million) Table 135. Europe Ankylosing Spondylitis Treatment Drug Market Share by Country (2021-2026) Table 136. Europe Ankylosing Spondylitis Treatment Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 137. Europe Ankylosing Spondylitis Treatment Drug Market Share Forecast by Country (2027-2032) Table 138. Asia-Pacific Ankylosing Spondylitis Treatment Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 139. Asia-Pacific Ankylosing Spondylitis Treatment Drug Market Size by Country (2021-2026) & (US$ Million) Table 140. Asia-Pacific Ankylosing Spondylitis Treatment Drug Market Share by Country (2021-2026) Table 141. Asia-Pacific Ankylosing Spondylitis Treatment Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 142. Asia-Pacific Ankylosing Spondylitis Treatment Drug Market Share Forecast by Country (2027-2032) Table 143. Latin America Ankylosing Spondylitis Treatment Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 144. Latin America Ankylosing Spondylitis Treatment Drug Market Size by Country (2021-2026) & (US$ Million) Table 145. Latin America Ankylosing Spondylitis Treatment Drug Market Share by Country (2021-2026) Table 146. Latin America Ankylosing Spondylitis Treatment Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 147. Latin America Ankylosing Spondylitis Treatment Drug Market Share Forecast by Country (2027-2032) Table 148. Middle East & Africa Ankylosing Spondylitis Treatment Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 149. Middle East & Africa Ankylosing Spondylitis Treatment Drug Market Size by Country (2021-2026) & (US$ Million) Table 150. Middle East & Africa Ankylosing Spondylitis Treatment Drug Market Share by Country (2021-2026) Table 151. Middle East & Africa Ankylosing Spondylitis Treatment Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 152. Middle East & Africa Ankylosing Spondylitis Treatment Drug Market Share Forecast by Country (2027-2032) Table 153. Research Programs/Design for This Report Table 154. Authors List of This Report Table 155. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Ankylosing Spondylitis Treatment Drug Product Image Figure 3. Global Ankylosing Spondylitis Treatment Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Ankylosing Spondylitis Treatment Drug Market Size (2021-2032) & (US$ Million) Figure 5. Global Ankylosing Spondylitis Treatment Drug Market Share by Region: 2025 VS 2032 Figure 6. Global Ankylosing Spondylitis Treatment Drug Market Share by Region (2021-2032) Figure 7. North America Ankylosing Spondylitis Treatment Drug Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Ankylosing Spondylitis Treatment Drug Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Ankylosing Spondylitis Treatment Drug Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Ankylosing Spondylitis Treatment Drug Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Ankylosing Spondylitis Treatment Drug Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Non-steroidal Anti-inflammatory Drugs Image Figure 13. Global Non-steroidal Anti-inflammatory Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Inhibitor Image Figure 15. Global Inhibitor Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Global Ankylosing Spondylitis Treatment Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 17. Global Ankylosing Spondylitis Treatment Drug Market Share by Type 2025 VS 2032 Figure 18. North America Ankylosing Spondylitis Treatment Drug Market Size Share by Type (2021-2032) Figure 19. Europe Ankylosing Spondylitis Treatment Drug Market Size Share by Type (2021-2032) Figure 20. Asia-Pacific Ankylosing Spondylitis Treatment Drug Market Size Share by Type (2021-2032) Figure 21. Latin America Ankylosing Spondylitis Treatment Drug Market Size Share by Type (2021-2032) Figure 22. Middle East and Africa Ankylosing Spondylitis Treatment Drug Market Size Share by Type (2021-2032) Figure 23. Retail Pharmacy Image Figure 24. Global Retail Pharmacy Market Size YoY Growth (2021-2032) & (US$ Million) Figure 25. Online Pharmacy Image Figure 26. Global Online Pharmacy Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Hospital Pharmacy Image Figure 28. Global Hospital Pharmacy Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. Other Image Figure 30. Global Other Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Global Ankylosing Spondylitis Treatment Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global Ankylosing Spondylitis Treatment Drug Market Share by Application 2025 VS 2032 Figure 33. North America Ankylosing Spondylitis Treatment Drug Market Size Share by Application (2021-2032) Figure 34. Europe Ankylosing Spondylitis Treatment Drug Market Size Share by Application (2021-2032) Figure 35. Asia-Pacific Ankylosing Spondylitis Treatment Drug Market Size Share by Application (2021-2032) Figure 36. Latin America Ankylosing Spondylitis Treatment Drug Market Size Share by Application (2021-2032) Figure 37. Middle East and Africa Ankylosing Spondylitis Treatment Drug Market Size Share by Application (2021-2032) Figure 38. Global Top 5 and 10 Ankylosing Spondylitis Treatment Drug Players Market Share by Revenue in 2025 Figure 39. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 40. North America Ankylosing Spondylitis Treatment Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 41. North America Ankylosing Spondylitis Treatment Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 42. North America Ankylosing Spondylitis Treatment Drug Market Share by Country (2021-2032) Figure 43. Europe Ankylosing Spondylitis Treatment Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. Europe Ankylosing Spondylitis Treatment Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Ankylosing Spondylitis Treatment Drug Market Share by Country (2021-2032) Figure 46. Asia-Pacific Ankylosing Spondylitis Treatment Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 47. Asia-Pacific Ankylosing Spondylitis Treatment Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 48. Asia-Pacific Ankylosing Spondylitis Treatment Drug Market Share by Country (2021-2032) Figure 49. Latin America Ankylosing Spondylitis Treatment Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Latin America Ankylosing Spondylitis Treatment Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Latin America Ankylosing Spondylitis Treatment Drug Market Share by Country (2021-2032) Figure 52. Middle East & Africa Ankylosing Spondylitis Treatment Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 53. Middle East & Africa Ankylosing Spondylitis Treatment Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 54. Middle East & Africa Ankylosing Spondylitis Treatment Drug Market Share by Country (2021-2032) Figure 55. Years Considered Figure 56. Research Process Figure 57. Key Executives Interviewed

Scope & coverage.

Types
  • Non-steroidal Anti-inflammatory Drugs
  • Inhibitor
Applications
  • Retail Pharmacy
  • Online Pharmacy
  • Hospital Pharmacy
  • Other
Companies covered
  • UCB
  • Abbott
  • Takeda
  • Eisai
  • Guojian Pharmaceutical
  • Celgen Pharm
  • Johson & Johson
  • Novartis
  • Merck
  • Maibo Pharma
  • Pfizer
  • Hisun Pharm
  • Bio-Thera Solutions
  • Amgen
  • Abbive
  • Mitsubishi Tanabe

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Ankylosing Spondylitis Treatment Drug Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Ankylosing Spondylitis Treatment Drug Market Size by Region (2021-2032)
  5. 1.4.1 Global Ankylosing Spondylitis Treatment Drug Market Size by Region (2021-2026)
  6. 1.4.2 Global Ankylosing Spondylitis Treatment Drug Market Size by Region (2027-2032)
  7. 1.5 Key Regions Ankylosing Spondylitis Treatment Drug Market Size (2021-2032)
  8. 1.5.1 North America Ankylosing Spondylitis Treatment Drug Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Ankylosing Spondylitis Treatment Drug Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Ankylosing Spondylitis Treatment Drug Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Ankylosing Spondylitis Treatment Drug Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Ankylosing Spondylitis Treatment Drug Market Size Growth Rate (2021-2032)
2 Ankylosing Spondylitis Treatment Drug Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Non-steroidal Anti-inflammatory Drugs
  3. 2.1.2 Inhibitor
  4. 2.2 Global Ankylosing Spondylitis Treatment Drug Market Size by Type
  5. 2.2.1 Global Ankylosing Spondylitis Treatment Drug Market Size Overview by Type (2021-2032)
  6. 2.2.2 Global Ankylosing Spondylitis Treatment Drug Historic Market Size Review by Type (2021-2026)
  7. 2.2.3 Global Ankylosing Spondylitis Treatment Drug Market Size Forecasted by Type (2027-2032)
  8. 2.3 Global Ankylosing Spondylitis Treatment Drug Market Size by Regions
  9. 2.3.1 North America Ankylosing Spondylitis Treatment Drug Market Size Breakdown by Type (2021-2026)
  10. 2.3.2 Europe Ankylosing Spondylitis Treatment Drug Market Size Breakdown by Type (2021-2026)
  11. 2.3.3 Asia-Pacific Ankylosing Spondylitis Treatment Drug Market Size Breakdown by Type (2021-2026)
  12. 2.3.4 South America Ankylosing Spondylitis Treatment Drug Market Size Breakdown by Type (2021-2026)
  13. 2.3.5 Middle East and Africa Ankylosing Spondylitis Treatment Drug Market Size Breakdown by Type (2021-2026)
3 Ankylosing Spondylitis Treatment Drug Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Retail Pharmacy
  3. 3.1.2 Online Pharmacy
  4. 3.1.3 Hospital Pharmacy
  5. 3.1.4 Other
  6. 3.2 Global Ankylosing Spondylitis Treatment Drug Market Size by Application
  7. 3.2.1 Global Ankylosing Spondylitis Treatment Drug Market Size Overview by Application (2021-2032)
  8. 3.2.2 Global Ankylosing Spondylitis Treatment Drug Historic Market Size Review by Application (2021-2026)
  9. 3.2.3 Global Ankylosing Spondylitis Treatment Drug Market Size Forecasted by Application (2027-2032)
  10. 3.3 Global Ankylosing Spondylitis Treatment Drug Market Size by Regions
  11. 3.3.1 North America Ankylosing Spondylitis Treatment Drug Market Size Breakdown by Application (2021-2026)
  12. 3.3.2 Europe Ankylosing Spondylitis Treatment Drug Market Size Breakdown by Application (2021-2026)
  13. 3.3.3 Asia-Pacific Ankylosing Spondylitis Treatment Drug Market Size Breakdown by Application (2021-2026)
  14. 3.3.4 South America Ankylosing Spondylitis Treatment Drug Market Size Breakdown by Application (2021-2026)
  15. 3.3.5 Middle East and Africa Ankylosing Spondylitis Treatment Drug Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Ankylosing Spondylitis Treatment Drug Industry Trends
  2. 4.2 Ankylosing Spondylitis Treatment Drug Industry Drivers
  3. 4.3 Ankylosing Spondylitis Treatment Drug Industry Opportunities and Challenges
  4. 4.4 Ankylosing Spondylitis Treatment Drug Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Ankylosing Spondylitis Treatment Drug Revenue (2021-2026)
  2. 5.2 Global Ankylosing Spondylitis Treatment Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Ankylosing Spondylitis Treatment Drug Key Company Headquarters & Area Served
  4. 5.4 Global Ankylosing Spondylitis Treatment Drug Company, Product Type & Application
  5. 5.5 Global Ankylosing Spondylitis Treatment Drug Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Ankylosing Spondylitis Treatment Drug Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Ankylosing Spondylitis Treatment Drug Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Ankylosing Spondylitis Treatment Drug Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 UCB
  2. 6.1.1 UCB Company Information
  3. 6.1.2 UCB Business Overview
  4. 6.1.3 UCB Ankylosing Spondylitis Treatment Drug Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 UCB Ankylosing Spondylitis Treatment Drug Product Portfolio
  6. 6.1.5 UCB Recent Developments
  7. 6.2 Abbott
  8. 6.2.1 Abbott Company Information
  9. 6.2.2 Abbott Business Overview
  10. 6.2.3 Abbott Ankylosing Spondylitis Treatment Drug Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Abbott Ankylosing Spondylitis Treatment Drug Product Portfolio
  12. 6.2.5 Abbott Recent Developments
  13. 6.3 Takeda
  14. 6.3.1 Takeda Company Information
  15. 6.3.2 Takeda Business Overview
  16. 6.3.3 Takeda Ankylosing Spondylitis Treatment Drug Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Takeda Ankylosing Spondylitis Treatment Drug Product Portfolio
  18. 6.3.5 Takeda Recent Developments
  19. 6.4 Eisai
  20. 6.4.1 Eisai Company Information
  21. 6.4.2 Eisai Business Overview
  22. 6.4.3 Eisai Ankylosing Spondylitis Treatment Drug Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Eisai Ankylosing Spondylitis Treatment Drug Product Portfolio
  24. 6.4.5 Eisai Recent Developments
  25. 6.5 Guojian Pharmaceutical
  26. 6.5.1 Guojian Pharmaceutical Company Information
  27. 6.5.2 Guojian Pharmaceutical Business Overview
  28. 6.5.3 Guojian Pharmaceutical Ankylosing Spondylitis Treatment Drug Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Guojian Pharmaceutical Ankylosing Spondylitis Treatment Drug Product Portfolio
  30. 6.5.5 Guojian Pharmaceutical Recent Developments
  31. 6.6 Celgen Pharm
  32. 6.6.1 Celgen Pharm Company Information
  33. 6.6.2 Celgen Pharm Business Overview
  34. 6.6.3 Celgen Pharm Ankylosing Spondylitis Treatment Drug Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 Celgen Pharm Ankylosing Spondylitis Treatment Drug Product Portfolio
  36. 6.6.5 Celgen Pharm Recent Developments
  37. 6.7 Johson & Johson
  38. 6.7.1 Johson & Johson Company Information
  39. 6.7.2 Johson & Johson Business Overview
  40. 6.7.3 Johson & Johson Ankylosing Spondylitis Treatment Drug Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Johson & Johson Ankylosing Spondylitis Treatment Drug Product Portfolio
  42. 6.7.5 Johson & Johson Recent Developments
  43. 6.8 Novartis
  44. 6.8.1 Novartis Company Information
  45. 6.8.2 Novartis Business Overview
  46. 6.8.3 Novartis Ankylosing Spondylitis Treatment Drug Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 Novartis Ankylosing Spondylitis Treatment Drug Product Portfolio
  48. 6.8.5 Novartis Recent Developments
  49. 6.9 Merck
  50. 6.9.1 Merck Company Information
  51. 6.9.2 Merck Business Overview
  52. 6.9.3 Merck Ankylosing Spondylitis Treatment Drug Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 Merck Ankylosing Spondylitis Treatment Drug Product Portfolio
  54. 6.9.5 Merck Recent Developments
  55. 6.10 Maibo Pharma
  56. 6.10.1 Maibo Pharma Company Information
  57. 6.10.2 Maibo Pharma Business Overview
  58. 6.10.3 Maibo Pharma Ankylosing Spondylitis Treatment Drug Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 Maibo Pharma Ankylosing Spondylitis Treatment Drug Product Portfolio
  60. 6.10.5 Maibo Pharma Recent Developments
  61. 6.11 Pfizer
  62. 6.11.1 Pfizer Company Information
  63. 6.11.2 Pfizer Business Overview
  64. 6.11.3 Pfizer Ankylosing Spondylitis Treatment Drug Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 Pfizer Ankylosing Spondylitis Treatment Drug Product Portfolio
  66. 6.11.5 Pfizer Recent Developments
  67. 6.12 Hisun Pharm
  68. 6.12.1 Hisun Pharm Company Information
  69. 6.12.2 Hisun Pharm Business Overview
  70. 6.12.3 Hisun Pharm Ankylosing Spondylitis Treatment Drug Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 Hisun Pharm Ankylosing Spondylitis Treatment Drug Product Portfolio
  72. 6.12.5 Hisun Pharm Recent Developments
  73. 6.13 Bio-Thera Solutions
  74. 6.13.1 Bio-Thera Solutions Company Information
  75. 6.13.2 Bio-Thera Solutions Business Overview
  76. 6.13.3 Bio-Thera Solutions Ankylosing Spondylitis Treatment Drug Revenue, Global Share and Gross Margin (2021-2026)
  77. 6.13.4 Bio-Thera Solutions Ankylosing Spondylitis Treatment Drug Product Portfolio
  78. 6.13.5 Bio-Thera Solutions Recent Developments
  79. 6.14 Amgen
  80. 6.14.1 Amgen Company Information
  81. 6.14.2 Amgen Business Overview
  82. 6.14.3 Amgen Ankylosing Spondylitis Treatment Drug Revenue, Global Share and Gross Margin (2021-2026)
  83. 6.14.4 Amgen Ankylosing Spondylitis Treatment Drug Product Portfolio
  84. 6.14.5 Amgen Recent Developments
  85. 6.15 Abbive
  86. 6.15.1 Abbive Company Information
  87. 6.15.2 Abbive Business Overview
  88. 6.15.3 Abbive Ankylosing Spondylitis Treatment Drug Revenue, Global Share and Gross Margin (2021-2026)
  89. 6.15.4 Abbive Ankylosing Spondylitis Treatment Drug Product Portfolio
  90. 6.15.5 Abbive Recent Developments
  91. 6.16 Mitsubishi Tanabe
  92. 6.16.1 Mitsubishi Tanabe Company Information
  93. 6.16.2 Mitsubishi Tanabe Business Overview
  94. 6.16.3 Mitsubishi Tanabe Ankylosing Spondylitis Treatment Drug Revenue, Global Share and Gross Margin (2021-2026)
  95. 6.16.4 Mitsubishi Tanabe Ankylosing Spondylitis Treatment Drug Product Portfolio
  96. 6.16.5 Mitsubishi Tanabe Recent Developments
7 North America
  1. 7.1 North America Ankylosing Spondylitis Treatment Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Ankylosing Spondylitis Treatment Drug Market Size by Country (2021-2026)
  3. 7.3 North America Ankylosing Spondylitis Treatment Drug Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Ankylosing Spondylitis Treatment Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Ankylosing Spondylitis Treatment Drug Market Size by Country (2021-2026)
  3. 8.3 Europe Ankylosing Spondylitis Treatment Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Ankylosing Spondylitis Treatment Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Ankylosing Spondylitis Treatment Drug Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Ankylosing Spondylitis Treatment Drug Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Ankylosing Spondylitis Treatment Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Ankylosing Spondylitis Treatment Drug Market Size by Country (2021-2026)
  3. 10.3 South America Ankylosing Spondylitis Treatment Drug Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Ankylosing Spondylitis Treatment Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Ankylosing Spondylitis Treatment Drug Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Ankylosing Spondylitis Treatment Drug Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst